The TRITON clinical trial programme: evaluation of the PARP inhibitor rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with homologous recombination deficiency (HRD)
作者
N.S. Cora,Bracarda Sergio,Ugo De Giorgi,Palmieri Giuseppe,Connie Simon,A. Wassim,Alon Angel,D. Gedske,Karim S. Fizazi,G. Eliahu,Hauschild Axel,Florence Joly,M. Ray,S.M. Axel,P. Josep Maria,Brieuc R. Sautois,S. Srikala,G. Tony,J.R. Charles,ichael S. Howard